Dermira, Inc. (DERM): Luis C. Pena , Chief Development Officer of Dermira, Inc. sold 10,000 shares on Jun 15, 2016. The Insider selling transaction was reported by the company on Jun 17, 2016 to the Securities and Exchange Commission. The shares were sold at $29.47 per share for a total value of $294,700.00 , the company said in a SEC Form 4 Filing.
Other Insider transactions have been reported by the company according to SEC Form 4, on Jun 15, 2016, Christopher M. Griffith (VP Corp. Dev. & Strategy) sold 4,405 shares at $30.16 per share price.On Jun 3, 2016, Thomas G Wiggans (CEO & Chairman of the Board) sold 11,000 shares at $31.34 per share price.Also, On Jun 3, 2016, Eugene A Bauer (Chief Medical Officer) sold 2,500 shares at $31.65 per share price.
Dermira Inc: On Wednesday, Jun 15, 2016 heightened volatility was witnessed in Dermira Inc which led to swings in the share price. The shares opened for trading at $29.35 and hit $29.95 on the upside , eventually ending the session at $29.89, with a gain of 2.08% or 0.61 points. The heightened volatility saw the trading volume jump to 3,20,329 shares. The 52-week high of the share price is $35.75 and the company has a market cap of $897 M . The 52-week low of the share price is at $15.89.
Company has been under the radar of several Street Analysts.Dermira Inc is Reiterated by Wedbush to Outperform and the brokerage firm has raised the Price Target to $ 46 from a previous price target of $42 .The Rating was issued on Jun 2, 2016.Dermira Inc is Reiterated by Needham to Buy and the brokerage firm has raised the Price Target to $ 46 from a previous price target of $42 .The Rating was issued on Jun 2, 2016.Dermira Inc is Reiterated by Needham to Buy and the brokerage firm has raised the Price Target to $ 42 from a previous price target of $38 .The Rating was issued on May 11, 2016.
Dermira Inc. is a specialty biopharmaceutical company focused on bringing medical dermatology products to dermatologists and their patients. The Company’s portfolio of five product candidates includes three late-stage product candidates. The late-stage product candidates are Cimzia (certolizumab pegol) which the Company is developing in collaboration with UCB Pharma S.A. (UCB) DRM04 and DRM01. Cimzia is an injectable biologic tumor necrosis factor-alpha inhibitor or TNF inhibitor that is approved and marketed by UCB for the treatment of numerous inflammatory diseases spanning multiple medical specialties. DRM04 is a topical small-molecule anticholinergic product the Company is developing for the treatment of hyperhidrosis or excessive sweating. DRM01 is a topical small-molecule sebum inhibitor the Company is developing for the treatment of acne.